Lercanidipin Genericon (Lercanidipine Hydrochloride)

Lercanidipine is a dihydropyridine calcium‑channel blocker used to manage elevated blood pressure.

• Hypertension: lowers systolic and diastolic pressure in adults with primary hypertension.
• Essential hypertension: assists patients in reaching guideline‑recommended blood pressure targets.
• Isolated systolic hypertension: provides arterial vasodilation to reduce isolated systolic elevations.

• Lercanidipine selectively inhibits L‑type calcium channels in vascular smooth muscle, preventing calcium influx that drives contraction. This results in arterial vasodilation, reduced peripheral resistance, and consequently a decrease in systemic blood pressure without significant negative inotropic effects on the heart.

Lercanidipine may be associated with several adverse reactions.

Common Side Effects

• Headache: mild to moderate intensity, often transient.
• Flushing: sensation of warmth and redness, usually resolves with continued therapy.
• Peripheral edema: swelling of ankles or lower legs due to vasodilation.
• Dizziness or light‑headedness, particularly after standing.
• Tachycardia or palpitations: increased heart rate in some patients.

Serious or Rare Side Effects

• Severe hypotension: marked drop in blood pressure leading to fainting.
• Angioedema: swelling of face, lips, tongue, or airway requiring urgent care.
• Myocardial infarction: rare reports of acute coronary events.
• Hepatic dysfunction: elevated liver enzymes or hepatitis.
• Anaphylactic reaction: life‑threatening allergic response.

Before initiating therapy, consider the following safety measures.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Hepatic impairment: use with caution; dose adjustment may be needed.
• Concomitant antihypertensives: assess risk of additive hypotensive effect.
• Elderly patients: start at lower dose and monitor for dizziness.
• Discontinuation: avoid abrupt cessation; taper if clinically indicated.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Lercanidipine can interact with several drug classes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may increase plasma concentrations and risk of hypotension.
• Concurrent use with other potent antihypertensives: can cause excessive blood pressure reduction.

Moderate Interactions (Monitor Closely)

• Grapefruit juice: may elevate drug levels modestly.
• CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce efficacy.
• NSAIDs: can blunt antihypertensive effect.
• Diuretics: may increase risk of electrolyte imbalance when combined.